Search results for "C63"

showing 10 items of 58 documents

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients Wi…

2021

There is a high need for novel treatment options in relapsed and refractory diffuse large B-cell lymphoma. Single agent mammalian target of rapamycin (mTOR) inhibitor treatment has shown promising efficacy in this entity. Here, we report on the results of the mTOR-inhibitor temsirolimus combined to standard rituximab-DHAP salvage regimen in a prospective, multicenter, phase II, open-label study. The STORM regimen consisted of rituximab 375 mg/m(2) (day 2) and DHAP (dexamethasone 40 mg day 3-6, cisplatinum 100 mg/m(2) day 3, cytarabine 2 × 2  g/m(2) day 4) with temsirolimus added on day 1 and 8 of a 21-day cycle, with 2 to 4 cycles planned. In part I, dose levels of 25, 50, 75, and 100 mg fo…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryHematology002ArticleTemsirolimusddc:TransplantationRegimenRefractoryInternal medicineDHAPmedicineCytarabineDiseases of the blood and blood-forming organsRituximabRC633-647.5businessDexamethasonemedicine.drug
researchProduct

Hedging foreign exchange rate risk: Multi-currency diversification

2016

Abstract This article proposes a multi-currency cross-hedging strategy that minimizes the exchange risk. The use of derivatives in small and medium-sized enterprises (SMEs) is not common but, despite its complexity, can be interesting for those with international activities. In particular, the reduction in the exchange risk borne through the use of natural multi-currency cross-hedging is measured, considering Conditional Value-at-Risk (CVaR) and Value-at-Risk (VaR) for measuring market risk instead of the variance. CVaR is minimized using linear programmes, while a multiobjective genetic algorithm is designed for minimizing VaR, considering two scenarios for each currency. The results obtai…

Organizational Behavior and Human Resource ManagementEconomicsFinancial economicsStrategy and Management0211 other engineering and technologiesDiversification (finance)02 engineering and technologyConditional Value-at-Riskddc:6500502 economics and businessEconometricsEconomicsBusinessG32G11Business and International ManagementHedge (finance)Rate riskMarketing021110 strategic defence & security studiesCVAR05 social sciencesValue-at-RiskBusiness FinanceManagementExpected shortfallC63Market riskCurrencyTourism Leisure and Hospitality ManagementMulti-currency diversificationMultiobjective genetic algorithm050211 marketingFinanceValue at riskCross-hedgingEuropean Journal of Management and Business Economics
researchProduct

Comment on “Worldwide Distribution of PK Deficiency: the Defect Seems Mainly Concentrated in West African Countries and the United States.”

2021

PKlcsh:RC633-647.5business.industry10031 Clinic for Angiology2720 HematologyPK DEFICIENCYDistribution (economics)610 Medicine & healthPK deficiency2725 Infectious Diseaseslcsh:Diseases of the blood and blood-forming organsHematologyUnited StatesWest African CountriesWest africanInfectious Diseases10032 Clinic for Oncology and HematologyDeficiencyMedicinebusinessSocioeconomicsLetter to the EditorMediterranean Journal of Hematology and Infectious Diseases
researchProduct

Pathobiology of Hodgkin Lymphoma

2010

Despite its well-known histological and clinical features, Hodgkin's lymphoma (HL) has recently been the object of intense research activity, leading to a better understanding of its phenotype, molecular characteristics, histogenesis, and possible mechanisms of lymphomagenesis. There is complete consensus on the B-cell derivation of the tumor in most cases, and on the relevance of Epstein-Barr virus infection and defective cytokinesis in at least a proportion of patients. The REAL/WHO classification recognizes a basic distinction between lymphocyte predominance HL (LP-HL) and classic HL (cHL), reflecting the differences in clinical presentation and behavior, morphology, phenotype, and molec…

Pathologymedicine.medical_specialtybusiness.industryMixed cellularityLymphocyteHematologyReview ArticleHistogenesismedicine.diseasePhenotypeVirusLymphomaPathobiologymedicine.anatomical_structurehemic and lymphatic diseasesmedicineHodgkin lymphomaDiseases of the blood and blood-forming organsRC633-647.5businessWho classificationHodgkin lymphoma; microenvironment.Hodgkin lymphomamicroenvironment.Advances in Hematology
researchProduct

Splenomegaly Impacts Prognosis in Essential Thrombocythemia and Polycythemia Vera: A Single Center Study

2019

Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with these diseases. We aimed to study the impact that such alteration has on thrombotic risk and on the survival of patients with essential thrombocythemia and patients with Polycythemia Vera (PV). We studied the relationship between splenomegaly (and its grade), thrombosis and survival in 238 patients with et and 165 patients with PV followed at our center between January 1997 and May 2019.

Pediatricsmedicine.medical_specialtySingle CenterArticle03 medical and health sciences0302 clinical medicinePolycythemia veraQuality of lifehemic and lymphatic diseasesmedicineMyelofibrosisPolycythemia VeraThrombotic riskessential thrombocythemiaEssential thrombocythemiabusiness.industrylcsh:RC633-647.5Hematologylcsh:Diseases of the blood and blood-forming organsmedicine.diseaseThrombosis030220 oncology & carcinogenesisSplenomegalysplenomegaly; polycythemia vera; essential thrombocythemiabusiness030215 immunologyHematology Reports; Volume 11; Issue 4; Pages: 8281
researchProduct

Nonsense-mediated decay mechanism is a possible modifying factor of clinical outcome in nonsense cd39 beta thalassemia genotype

2012

Nonsense-mediated mRNA decay (NMD) is a surveillance system to prevent the synthesis of non-functional proteins. In β-thalassemia, NMD may have a role in clinical outcome. An example of premature translation stop codons appearing for the first time is the β-globin cd39 mutation; when homozygous, this results in a severe phenotype. The aim of this study was to determine whether the homozygous nonsense cd39 may have a milder phenotype in comparison with IVS1,nt110/cd39 genotype. Genotypes have been identified from a cohort of 568 patients affected by β-thalassemia. These genotypes were compared with those found in 577 affected fetuses detected among 2292 prenatal diagnoses. The…

Pediatricsmedicine.medical_specialtymedia_common.quotation_subjectNonsense-mediated decayNonsenseBeta thalassemiaBiologynonsense-mediated mRNA decay; beta-thalassemia; clinical outcame; beta-globin gene mutationsmedicine.diseaseGastroenterologynonsense-mediated mRNA decay beta-thalassemia beta-globin gene mutationsnonsense-mediated mRNA decay beta-thalassemia clinical outcame beta-globin gene mutations.Internal medicineGenotypemedicineDiseases of the blood and blood-forming organsRC633-647.5media_commonThalassemia Reports
researchProduct

The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep

2020

The Essential Thrombocythemia is a Chronic Philadelphia-negative Myeloproliferative Neoplasm characterized by a survival curve that is only slightly worse than that of age- and sex-adjusted healthy population. The criteria for diagnosis were reviewed in 2016 by WHO. The incidence varies from 0.2 to 2.5:100 000 people per year, with a prevalence of 38 to 57 cases per 100 000 people. The main characteristics of ET are the marked thrombocytosis and the high frequency of thrombosis. The spectrum of symptoms is quite wide, but fatigue results to be the most frequent. Thrombosis is frequently observed, often occurring before or at the time of diagnosis. The classification of thrombotic risk has …

Plateletsmedicine.medical_specialtylcsh:RC633-647.5Essential thrombocythemiabusiness.industryPlateletlcsh:Diseases of the blood and blood-forming organsHematologyReviewMyeloproliferative Neoplasmmedicine.diseaseGastroenterology03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisDigInternal medicinemedicineMyeloproliferative NeoplasmsThrombocythemiabusinessSurvival analysisMyeloproliferative neoplasm030215 immunologySlightly worse
researchProduct

Homogeneous actions on the random graph

2018

We show that any free product of two countable groups, one of them being infinite, admits a faithful and homogeneous action on the Random Graph. We also show that a large class of HNN extensions or free products, amalgamated over a finite group, admit such an action and we extend our results to groups acting on trees. Finally, we show the ubiquity of finitely generated free dense subgroups of the automorphism group of the Random Graph whose action on it have all orbits infinite.

Random graphFinite group20B22 (primary) 20E06 20E05 05C63 54E52 (secondary)Group Theory (math.GR)Homogeneous actions16. Peace & justicegroups acting on trees[MATH.MATH-GR]Mathematics [math]/Group Theory [math.GR]Action (physics)CombinatoricsMathematics::Group TheoryFree productHomogeneousBaire category theoremFOS: MathematicsDiscrete Mathematics and CombinatoricsCountable setBaire category theoremfree groupsGeometry and TopologyFinitely-generated abelian groupMathematics - Group TheoryMSC: 20B22 (primary); 20E06 20E05 05C63 54E52 (secondary)random graphMathematicsGroups, Geometry, and Dynamics
researchProduct

A semiparametric approach to estimate reference curves for biophysical properties of the skin

2006

Reference curves which take one covariable into account such as the age, are often required in medicine, but simple systematic and efficient statistical methods for constructing them are lacking. Classical methods are based on parametric fitting (polynomial curves). In this chapter, we describe a new methodology for the estimation of reference curves for data sets, based on nonparametric estimation of conditional quantiles. The derived method should be applicable to all clinical or more generally biological variables that are measured on a continuous quantitative scale. To avoid the curse of dimensionality when the covariate is multidimensional, a new semiparametric approach is proposed. Th…

Statistics::TheoryKernel density estimationcomputer.software_genre01 natural sciences010104 statistics & probability0502 economics and businessCovariateSliced inverse regressionApplied mathematicsStatistics::MethodologySemiparametric regression0101 mathematics[SHS.ECO] Humanities and Social Sciences/Economics and Finance050205 econometrics MathematicsParametric statisticsDimensionality reduction05 social sciencesNonparametric statistics[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie[SHS.ECO]Humanities and Social Sciences/Economics and Finance3. Good health[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieC140;C630Data miningcomputerQuantile
researchProduct

Microenvironment-centred dynamics in aggressive B-cell lymphomas.

2012

Aggressive B-cell lymphomas share high proliferative and invasive attitudes and dismal prognosis despite heterogeneous biological features. In the interchained sequence of events leading to cancer progression, neoplastic clone-intrinsic molecular events play a major role. Nevertheless, microenvironment-related cues have progressively come into focus as true determinants for this process. The cancer-associated microenvironment is a complex network of nonneoplastic immune and stromal cells embedded in extracellular components, giving rise to a multifarious crosstalk with neoplastic cells towards the induction of a supportive milieu. The immunological and stromal microenvironments have been cl…

Stromal cellMicroenvironmentHematologyReview ArticleBiologyMicroenvironment; aggressive B-cell lymphomasCrosstalk (biology)Immune systemmedicine.anatomical_structureImmunologymedicineDiseases of the blood and blood-forming organsRC633-647.5Indolent lymphomasB cellaggressive B-cell lymphomas
researchProduct